Analyst Rating Update on Myriad Genetics (MYGN)

Myriad Genetics (MYGN) : Zacks Investment Research ranks Myriad Genetics (MYGN) as 4, which is a Sell recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 2 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.41, which indicates as a Buy.

Myriad Genetics (MYGN) stock is expected to deviate a maximum of $9.85 from the average target price of $37.75 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $50 and the most muted being $25.

Company shares have received an average consensus rating of Hold for the current week


Myriad Genetics (NASDAQ:MYGN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.83 and $30.36 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $31.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $31.42, notching a gain of 1.95% for the day. The total traded volume was 756,872 . The stock had closed at $30.82 on the previous day.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.